

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai Haohai Biological Technology Co., Ltd.\***

**上海昊海生物科技股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6826)**

## **AMENDMENTS TO THE ARTICLES OF ASSOCIATION**

The amendments of the articles of association (the “**Articles of Association**”) of Shanghai Haohai Biological Technology Co., Ltd.\* (the “**Company**”) was approved by the meeting of the board of directors of the Company (the “**Board**”) held on 28 October 2021. The Board was authorized to approve the amendments to the Articles of Association pursuant to the First Repurchase Mandate (as defined below) and the Second Repurchase Mandate (as defined below).

This announcement is made by the Company pursuant to Rules 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

References are made to the Company’s resolutions regarding granting the general mandate to the Board to repurchase H shares of the Company (the “**H Shares**”) approved at the 2020 first extraordinary general meeting, the 2020 first A shareholders’ class meeting and the 2020 first H shareholders’ class meeting convened on 14 February 2020 (the “**First Repurchase Mandate**”); and the Company’s resolutions regarding granting the general mandate to the Board to repurchase the H Shares approved at the 2019 annual general meeting, the 2020 second A shareholders’ class meeting and the 2020 second H shareholders’ class meeting convened on 29 June 2020 (the “**Second Repurchase Mandate**”).

Pursuant to the First Repurchase Mandate, the Company repurchased a total of 638,700 H Shares during the period from 27 March 2020 to 8 May 2020, and cancelled the respective repurchased H Shares on 3 July 2020. Pursuant to the Second Repurchase Mandate, the Company repurchased a total of 584,500 H Shares during the period from 21 July 2020 to 3 September 2020 and cancelled the respective repurchased H Shares on 19 March 2021; and the Company subsequently repurchased a total of 800,000 H Shares during the period from 26 April 2021 to 14 May 2021 and cancelled the respective repurchased H Shares on 14 July 2021.

After cancellation of all of the repurchased H shares above, the total share capital of the Company has been reduced from 177,845,300 shares to 175,822,100 shares, and the registered capital of the Company has been reduced from RMB177,845,300 to RMB175,822,100. At the meeting of the Board held on 28 October 2021, the Board considered and approved, among others, the proposal to amend the Articles of Association in accordance with such changes in the total share capital and registered capital of the Company. The Board was also authorized by the First Repurchase Mandate and Second Repurchase Mandate to carry out cancellation procedures for the repurchased shares, reduce registered capital, make corresponding amendments to the Articles of Association in respect of the changes in the total share capital and shareholding structure, etc., and to carry out relevant statutory registrations and filing procedures within and outside The People's Republic of China (the "PRC"). In view of the above, these amendments to the Articles of Association will not be submitted once again for consideration and approval at the general meeting of the Company.

The amendments to the Articles of Association are as follows:

No.	Existing Articles	Revised Articles
1	<p><b>Article 18</b> Upon establishment of the Company, as approved by the securities regulatory authorities under the State Council and the Hong Kong Stock Exchange, the Company issued 40,045,300 ordinary shares through initial public offering, all are H shares.</p> <p>Upon completion of the aforesaid issue of H shares, the Company's shareholding structure is: …….</p> <p>On 27 September 2019, approved by China Security Regulatory Commission ("CSRC") (Zheng Jian Xu Ke [2019] No. 1793), the Company initially public offered 17,800,000 Domestic Shares, such Domestic Shares issued and issued previous by the Company are listed on 30 October 2019. The capital structure of the Company: total share capital is 177,845,300 shares, of which 137,800,000 are A shares, representing 77.483% of ordinary shares capital of the Company, 40,045,300 are H shares, representing 22.517% of ordinary shares capital of the Company.</p>	<p><b>Article 18</b> Upon establishment of the Company, as approved by the securities regulatory authorities under the State Council and the Hong Kong Stock Exchange, the Company issued 40,045,300 ordinary shares through initial public offering, all are H shares.</p> <p>Upon completion of the aforesaid issue of H shares, the Company's shareholding structure is: …….</p> <p>On 27 September 2019, approved by China Security Regulatory Commission ("CSRC") (Zheng Jian Xu Ke [2019] No. 1793), the Company initially public offered 17,800,000 Domestic Shares, such Domestic Shares issued and issued previous by the Company are listed on 30 October 2019. The capital structure of the Company: total share capital is 175,822,100 shares, of which 137,800,000 are A shares, representing 77.483% of ordinary shares capital of the Company, 40,045,300 are H shares, representing 22.517% of ordinary shares capital of the Company.</p> <p><u>Upon obtaining approval at the Company's 2020 first extraordinary general meeting, 2020 first A shareholders' class meeting and 2020 first H shareholders' class meeting, the Company repurchased and cancelled 638,700 H shares. Upon obtaining approval at the Company's 2019 annual general meeting, 2020 second A shareholders' class meeting and 2020 second H shareholders' class meeting, the Company repurchased and cancelled 1,384,500 H shares. After cancellation of the respective repurchased H shares, the share capital structure of the Company is as follows: the total share capital is 175,822,100 shares, of which 137,800,000 are A shares, representing 78.375% of the ordinary share capital of the Company, and 38,022,100 are H shares, representing 21.625% of the ordinary share capital of the Company.</u></p>

No.	Existing Articles	Revised Articles
2	<p><b>Article 21</b> Prior to the issuance of H shares, the registered capital of the Company is RMB177,845,300.</p>	<p><b>Article 21</b> <del>Prior to the issuance of H shares, the</del> <u>The</u> registered capital of the Company is RMB<u>175,822,100</u>.</p>

Save for the above amendments to the Articles of Association, other provisions of the Articles of Association will remain unchanged. The above amendments to the Articles of Association shall become effective from 28 October 2021.

The English version of the above amendments to the Articles of Association is an unofficial translation of its Chinese version. In case of any discrepancies, the Chinese version shall prevail.

By order of the Board  
**Shanghai Haohai Biological Technology Co., Ltd.\***  
*Chairman*  
**Hou Yongtai**

Shanghai, the PRC, 28 October 2021

*As at the date of this announcement, the executive directors of the Company are Dr. Hou Yongtai, Mr. Wu Jianying, Ms. Chen Yiyi and Mr. Tang Minjie; the non-executive directors of the Company are Ms. You Jie and Mr. Huang Ming; and the independent non-executive directors of the Company are Ms. Li Yingqi, Mr. Jiang Zhihong, Mr. Su Zhi, Mr. Yang Yushe and Mr. Zhao Lei.*

\* *For identification purpose only*